« Return to News | Drug Sponsors

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

"Shire is a fast growing company with high ambitions and our U.K. business continues to evolve; we seek to play a role in the development and growth of our industry so joining the ABPI will be one way of contributing to this,” said Nicola Massey vice president and general manager of the U.K. International Speciality Business and Janis Clayton vice president and general manager of the U.K. Human Genetics Therapy Business, Shire. “We are looking forward to working with the ABPI and engaging with their wider membership on issues that are important to all of us but most importantly to fight for the needs of our patients."

Nicola Massey will join the ABPI board of management with immediate effect.

Stephen Whitehead, chief executive of the ABPI, said, "I’m delighted Shire has joined the ABPI. This is a critical time for industry and a very important time for our members. The ABPI provides a strong voice and strong leadership for our members and we are very happy to be supporting Shire as we go forward."

Shire is focused on chronic symptomatic diseases in areas of unmet needs where the impact of their medicines can make an immediate and tangible difference for patients.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.